Clinical trials: Hepatic Encephalopathy
Hepatic Encephalopathy
Efficacy of Lactoferrin as an Adjunct Therapy in Patients With Hepatic Encephalopathy
The aim of this study is to evaluate the efficacy of lactoferrin as an adjunct therapy in improving clinical symptoms and laboratory indices in individuals with hepatic encephalopathy.
- Trial name
- NCT06072521
- Testing
- Lactoferrin Bovine
- Where
- Egypt
- Volunteers
- 45 people
- Sponsor
- Al-Azhar University
Hepatic Encephalopathy
Hepatic Encephalopathy Prevention With Polydextrose After TIPS: Pilot Study (POEME)
TIPS is a standard for the treatment of portal hypertension related complications. However, it remains at risk of HE after TIPS (around 40% the first year). Dysbiosis plays a key role in pathophysiology of HE.
- Trial name
- POEME (NCT05206487)
- Testing
- Polydextrose
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Toulouse
Hepatic Encephalopathy
The Effects of Nitazoxanide in Hepatic Encephalopathy
Evaluating the efficacy and safety of nitazoxanide in comparison to standard treatment in patients with grade II-III hepatic encephalopathy (HE).
- Trial name
- NCT02334163
- Testing
- Nitazoxanide, Oral lactulose, Metronidazole
- Where
- Egypt
- Volunteers
- 36 people
- Sponsor
- Ain Shams University
Hepatic Encephalopathy
Polyethylene Glycol Versus Lactulose on Hepatic Encephalopathy in Patients With Cirrhosis;(PEGHE Trial)
Hepatic Encephaopathy is a common complication occurring in patients with Liver cirrhosis. Patients usually develop mild confusion, sleep disturbance or obtundation.
- Trial name
- PEGHE (NCT04436601)
- Testing
- Polyethylene Glycols, Lactulose
- Where
- Pakistan
- Volunteers
- 102 people
- Sponsor
- Aga Khan University
Minimal Hepatic Encephalopathy
Psychometric Hepatic Encephalopathy Score in Prediction of Minimal Hepatic Encephalopathy in Compensated Cirrhotic Patients
Minimal hepatic encephalopathy (MHE) is a covert form of hepatic encephalopathy associated with cognitive and psychomotor impairment in patients with compensated liver cirrhosis.
- Trial name
- PHES-MHE (NCT07272707)
- Testing
- Psychometric Hepatic Encephalopathy Score (PHES)
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Sohag University
Liver Cirrhosis
Embolization of Large Spontaneous Portosystemic Shunts for the Prevention of Post-TIPS Hepatic Encephalopathy
The purpose of this study is to determine whether transjugular intrahepatic portosystemic shunt (TIPS) combined with large spontaneous portosystemic shunts embolization are effective in the prevention of hepatic encephalopathy…
- Trial name
- NCT02156232
- Testing
- TIPS, SPSS embolization
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Air Force Military Medical University, China
Hepatic Encephalopathy
Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy
The primary purpose of this study is to evaluate the safety and effectiveness of Ammonul® in subjects who become hospitalized with Grade 3 or 4 hepatic encephalopathy (HE).
- Trial name
- NCT00597909
- Testing
- sodium phenylacetate and sodium benzoate injection 10% / 10%
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- Amgen
Hepatic Pathology (Fibrosis, Cirrhosis, Porto Systemic Shunts)
Development of a Cognitive Tool for Rapid and Reliable Screening of Minimal Hepatic Encephalopathy: Pilot Study
The aim of this project is to evaluate the sensitivity and specificity of a cognitive test toward the presence of minimal hepatic encephalopathy (MHE).
- Trial name
- BLOCK-HE (NCT06619106)
- Testing
- Cognitive test
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatic Encephalopathy, Cirrhosis
Metobolomics in the Characterisation of HE
Hepatic encephalopathy is (HE) defined by the neurological and/or neuropsychological symptoms caused by an acute or chronic liver disease and/or a portosystemic shunt.
- Trial name
- METABO-EH (NCT06245473)
- Testing
- blood sample
- Where
- 2 sites in France
- Volunteers
- 1 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cirrhosis, Portal Hypertension
Evaluation of Minimal Hepatic Encephalopathy in Patients With Cirrhosis and Portal Hypertension
Minimal hepatic encephalopathy (MHE) is a subclinical cognitive impairment and represents the mildest type of hepatic encephalopathy (HE).
- Trial name
- Evencipor (NCT04807803)
- Testing
- Assessment of Minimal hepatic encephalopathy (MHE)
- Where
- 2 sites in France
- Volunteers
- 82 people
- Sponsor
- IHU Strasbourg
Hepatic Encephalopathy
Efficacy of Combined Oral L-ornithine-L-aspartate and Lactulose in Patients With Hepatic Encephalopathy
Hypothesis: Is the combination of oral L-ornithine-L-aspartate and lactulose more efficacious than oral lactulose alone in treatment of hepatic encephalopathy? Study design; Randomized, double-blinded, placebo controlled trial
- Trial name
- NCT00740142
- Testing
- L-ornithine-L-aspartate and lactulose
- Where
- Thailand
- Volunteers
- 35 people
- Sponsor
- Mahidol University
Minimal Hepatic Encephalopathy
A Nutritional Approach to Minimal Hepatic Encephalopathy
This trial will study a possible effect of standard Israeli breakfast (30% of caloric value and 21 gram protein) on cognitive and executive functions (working memory, visual memory, concentration and coordination), on patients…
- Trial name
- NCT01083446
- Testing
- Nutritional Intervention
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Hepatic Encephalopathy, Acute-On-Chronic Liver Failure
Intravenous BCAA for HE in ACLF (BCAA-HE-ACLF)
This multi-centric study analyses the effect of intravenous branched-chain amino acids (BCAA) on overt HE in patients with ACLF.
- Trial name
- NCT05700695
- Testing
- Branch Chain Amino Acid, Lactulose
- Where
- India
- Volunteers
- 114 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Carcinoma, Hepatocellular
A Post-marketing Observational Study on Risk Factors for Hepatic Encephalopathy in Participants With Unresectable Hepatocellular Carcinoma
This study is a post-marketing observational study of lenvatinib in participants with unresectable hepatocellular carcinoma. The primary objective of this study is assessment of risk factors for hepatic encephalopathy.
- Trial name
- NCT03663114
- Testing
- Lenvatinib
- Where
- 2 sites in Japan
- Volunteers
- 713 people
- Sponsor
- Eisai Inc.
Acute Liver Failure, Hepatic Encephalopathy
The Effect of Prometheus (R) Liver Support Dialysis on Cerebral Metabolism in Acute Liver Failure
The main objective of this study is to investigate the effect of Prometheus liver support dialysis on intracranial pressure, cerebral metabolism and circulation in patients with acute liver failure.
- Conditions
- Acute Liver Failure, Hepatic Encephalopathy, Intracranial Hypertension
- Trial name
- NCT00655304
- Testing
- Prometheus (R) liver support dialysis, CVVHDF (Continuously Veno-Venous Hemodiafiltration)
- Where
- Denmark
- Volunteers
- 8 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Hepatic Encephalopathy
S. Endotoxin, Inflammatory Mediators and MRS Before and After Treatment in MHE
The purpose of this study is to examine S.endotoxins , inflammatory mediators and Magnetic Resonance Spectroscopy (MRS) before and after treatment in patients of cirrhosis and minimal hepatic encephalopathy.
- Trial name
- endtxninHE (NCT01446523)
- Testing
- Lactulose
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Govind Ballabh Pant Hospital
Encephalopathy, Hepatic
Nitazoxanide Plus Lactulose Versus Lactulose Alone Treatment of Hepatic Encephalopathy
Hepatic encephalopathy (HE) is a reversible neuropsychiatric syndrome associated with chronic and acute liver dysfunction. It is characterized by cognitive and motor deficits of varying severity.
- Trial name
- NCT02464124
- Testing
- Nitazoxanide, Lactulose
- Where
- Egypt
- Volunteers
- 120 people
- Sponsor
- Sherief Abd-Elsalam
Caregivers
CAREGIVER: A Trial to Improve the Burden and Distress of Caring for Persons With Decompensated Cirrhosis
The goal of this study is to enroll caretakers of patients with decompensated cirrhosis to determine if written emotional disclosure or resilience training interventions reduce distress and burden among primary informal…
- Trial name
- NCT04205396
- Testing
- Written emotional disclosure, Resilience training, No treatment
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- University of Michigan
Acute on Chronic Liver Failure (ACLF), Hepatic Encephalopathy (HE)
RENEW: Study of Porcine Liver Support in Participants With Acute-on-Chronic Liver Failure
This is a Phase 1/2, first-in-human (FIH) safety, proof-of-concept, two-part study of the genetically-engineered EGEN-5784 liver in combination with the metra® extra-corporeal liver cross-circulation (ELC) system in participants…
- Trial name
- NCT07429838
- Testing
- metra® Extracorporeal Liver Cross-Circulation (ELC) system (OrganOx), EGEN-5784 (genetically engineered porcine liver)
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- eGenesis, INC
Hepatic Encephalopathy
PEG (Polyethylene Glycol)Versus Lactulose For Treatment Of Overt Hepatic Encephalopathy
The current standard of care for patients with HE includes non-absorbable disaccharides(lactulose);The chemical name for lactulose is 4-O-β-D-galactopyranosyl-D-fructofuranose.The exact mode of action by lactulose is thought to…
- Trial name
- NCT03100513
- Testing
- Lactulose, Polyethylene Glycol
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Sherief Abd-Elsalam